The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

Christina Justenhoven, Ofure Obazee, Stefan Winter, Fergus J. Couch, Janet E. Olson, Per Hall, Ulf Hannelius, Jingmei Li, Keith Humphreys, Gianluca Severi, Graham Giles, Melissa Southey, Laura Baglietto, Peter A. Fasching, Matthias W. Beckmann, Arif B. Ekici, Ute Hamann, Christian Baisch, Volker Harth, Sylvia RabsteinAnne Lotz, Beate Pesch, Thomas Brüning, Yon Dschun Ko, Hiltrud Brauch

Research output: Contribution to journalLetter

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)347-350
Number of pages4
JournalBreast Cancer Research and Treatment
Volume131
Issue number1
DOIs
StatePublished - Jan 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Justenhoven, C., Obazee, O., Winter, S., Couch, F. J., Olson, J. E., Hall, P., Hannelius, U., Li, J., Humphreys, K., Severi, G., Giles, G., Southey, M., Baglietto, L., Fasching, P. A., Beckmann, M. W., Ekici, A. B., Hamann, U., Baisch, C., Harth, V., ... Brauch, H. (2012). The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Research and Treatment, 131(1), 347-350. https://doi.org/10.1007/s10549-011-1827-1